Steik Jason Paul
Chief Clinical Officer
Steik Jason Paul has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 10, 2026.
On the most recent filing, Steik Jason Paul is listed as Chief Clinical Officer at Pennant Group, Inc. Inside the rolling window, Steik Jason Paul reported no open-market purchases and 1 open-market sale totaling $54K in PNTG.
Companies traded
Other insiders at PNTG
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$54K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Steik Jason Paul made?
Steik Jason Paul has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Steik Jason Paul trade?
Steik Jason Paul has filed SEC Form 4 disclosures for 1 company, including PNTG.
When was Steik Jason Paul's most recent SEC Form 4 filing?
Steik Jason Paul's most recent SEC Form 4 filing on Tracefour is dated Aug 10, 2026.
What is Steik Jason Paul's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Steik Jason Paul is listed as Chief Clinical Officer.
What is Steik Jason Paul's total buy and sell value in the current window?
Inside the rolling retention window, Steik Jason Paul bought $0 and sold $54K based on SEC Form 4 filings.
What was Steik Jason Paul's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,394 PNTG shares on 2026-08-06, worth $54K, per SEC Form 4 filings.